share_log

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(8.1%)

SEC announcement ·  Feb 9 18:06
Summary by Moomoo AI
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on February 7, 2024, indicating a significant stake in CRISPR Therapeutics AG. The filing, dated December 29, 2023, shows that CII has beneficial ownership of 6,420,736 shares of CRISPR Therapeutics' common stock, representing 8.1% of the company's class of securities believed to be outstanding. The shares are held in the ordinary course of business, with no intention of influencing the control of the issuer. CII has sole voting power over 6,374,948 shares and sole dispositive power over all 6,420,736 shares, with no shared voting or dispositive power reported.
Capital International Investors (CII), a division of Capital Research and Management Company, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on February 7, 2024, indicating a significant stake in CRISPR Therapeutics AG. The filing, dated December 29, 2023, shows that CII has beneficial ownership of 6,420,736 shares of CRISPR Therapeutics' common stock, representing 8.1% of the company's class of securities believed to be outstanding. The shares are held in the ordinary course of business, with no intention of influencing the control of the issuer. CII has sole voting power over 6,374,948 shares and sole dispositive power over all 6,420,736 shares, with no shared voting or dispositive power reported.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more